<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">26423553</PMID>
<DateCompleted>
<Year>2016</Year>
<Month>09</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">2352-3018</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>2</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2015</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>The lancet. HIV</Title>
<ISOAbbreviation>Lancet HIV</ISOAbbreviation>
</Journal>
<ArticleTitle>Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.</ArticleTitle>
<Pagination>
<MedlinePgn>e393-400</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/S2352-3018(15)00127-7</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S2352-3018(15)00127-7</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Widespread HIV screening and access to highly active antiretroviral treatment (ART) were cost effective in mathematical models, but population-level implementation has led to questions about cost, value, and feasibility. In 1996, British Columbia, Canada, introduced universal coverage of drug and other health-care costs for people with HIV/AIDS and and began extensive scale-up in access to ART. We aimed to assess the cost-effectiveness of ART scale-up in British Columbia compared with hypothetical scenarios of constrained treatment access.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Using comprehensive linked population-level data, we populated a dynamic, compartmental transmission model to simulate the HIV/AIDS epidemic in British Columbia from 1997 to 2010. We estimated HIV incidence, prevalence, mortality, costs (in 2010 CAN$), and quality-adjusted life-years (QALYs) for the study period, which was 1997-2010. We calculated incremental cost-effectiveness ratios from societal and third-party-payer perspectives to compare actual practice (true numbers of individuals accessing ART) to scenarios of constrained expansion (75% and 50% probability of accessing ART). We also investigated structural and parameter uncertainty.</AbstractText>
<AbstractText Label="FINDINGS" NlmCategory="RESULTS">Actual practice resulted in 263 averted incident cases compared with 75% of observed access and 676 averted cases compared with 50% of observed access to ART. From a third-party-payer perspective, actual practice resulted in incremental cost-effectiveness ratios of $23 679 per QALY versus 75% access and $24 250 per QALY versus 50% access. From a societal perspective, actual practice was cost saving within the study period. When the model was extended to 2035, current observed access resulted in cumulative savings of $25·1 million compared with the 75% access scenario and $65·5 million compared with the 50% access scenario.</AbstractText>
<AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">ART scale-up in British Columbia has decreased HIV-related morbidity, mortality, and transmission. Resulting incremental cost-effectiveness ratios for actual practice, derived within a limited timeframe, were within established cost-effectiveness thresholds and were cost saving from a societal perspective.</AbstractText>
<AbstractText Label="FUNDING" NlmCategory="BACKGROUND">BC Ministry of Health, National Institute of Drug Abuse at the US National Institutes of Health.</AbstractText>
<CopyrightInformation>Copyright © 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nosyk</LastName>
<ForeName>Bohdan</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Min</LastName>
<ForeName>Jeong E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lima</LastName>
<ForeName>Viviane D</ForeName>
<Initials>VD</Initials>
<AffiliationInfo>
<Affiliation>Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hogg</LastName>
<ForeName>Robert S</ForeName>
<Initials>RS</Initials>
<AffiliationInfo>
<Affiliation>BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Montaner</LastName>
<ForeName>Julio S G</ForeName>
<Initials>JS</Initials>
<AffiliationInfo>
<Affiliation>BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: jmontaner@cfenet.ubc.ca.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<CollectiveName>STOP HIV/AIDS study group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>DP1 DA026182</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DA036307</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1DP1DA026182</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01DA036307-01</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2015</Year>
<Month>07</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Lancet HIV</MedlineTA>
<NlmUniqueID>101645355</NlmUniqueID>
<ISSNLinking>2352-3018</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CitationSubset>X</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Lancet HIV. 2015 Sep;2(9):e358-9</RefSource>
<PMID Version="1">26423542</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D023241">Antiretroviral Therapy, Highly Active</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D001955">British Columbia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018791">CD4 Lymphocyte Count</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000191">economics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003362">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005240">Feasibility Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015658">HIV Infections</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000191">economics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017048">Health Care Costs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008962">Models, Theoretical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019057">Quality-Adjusted Life Years</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Barrios</LastName>
<ForeName>Rolando</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Daly</LastName>
<ForeName>Patty</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Gustafson</LastName>
<ForeName>Reka</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Kendall</LastName>
<ForeName>Perry R W</ForeName>
<Initials>PR</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>McGowan</LastName>
<ForeName>Gina</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Day</LastName>
<ForeName>Irene</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Heath</LastName>
<ForeName>Kate</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Hogg</LastName>
<ForeName>Robert S</ForeName>
<Initials>RS</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Montaner</LastName>
<ForeName>Julio S G</ForeName>
<Initials>JS</Initials>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Nosyk</LastName>
<ForeName>Bohdan</ForeName>
<Initials>B</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2015</Year>
<Month>04</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2015</Year>
<Month>06</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2015</Year>
<Month>06</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2015</Year>
<Month>10</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2015</Year>
<Month>10</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2016</Year>
<Month>9</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">26423553</ArticleId>
<ArticleId IdType="pii">S2352-3018(15)00127-7</ArticleId>
<ArticleId IdType="doi">10.1016/S2352-3018(15)00127-7</ArticleId>
<ArticleId IdType="pmc">PMC4610179</ArticleId>
<ArticleId IdType="mid">NIHMS715943</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>PLoS Med. 2012;9(7):e1001259</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22802739</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2011 Aug 11;365(6):493-505</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21767103</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2011 Apr 23;377(9775):1429-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21497898</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Value Health. 2012 Sep-Oct;15(6):828-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22999132</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2013 Feb 22;339(6122):966-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23430656</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>HIV Med. 2013 Oct;14(9):581-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24033869</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):653-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24135777</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2013 Nov 9;382(9904):1564-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23993281</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Infect Dis. 2014 Jan;14(1):40-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24076277</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2013;8(12):e81355</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24367482</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2014 Feb 6;370(6):581-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24499229</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2014;9(2):e87872</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24533061</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>AIDS. 2014 Jun 19;28(10):1489-98</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24732775</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):16202-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25313068</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pharmacoeconomics. 2015 Mar;33(3):243-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25404425</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Med Care. 2014 Apr;52(4):362-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24848208</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2015 Apr 18;385(9977):1482-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25933264</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Intern Med. 2010 Dec 21;153(12):778-89</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21173412</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Subst Abuse Treat. 2010 Jul;39(1):22-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20418051</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2009 Jan 3;373(9657):48-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19038438</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2006 Mar 11;367(9513):817-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16530575</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA. 1998 Jan 14;279(2):130-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9440663</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Intern Med. 1997 Jun 15;126(12):946-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9182471</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2000 Mar 30;342(13):921-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10738050</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>